Skip to main content
Top
Published in: Current Treatment Options in Oncology 12/2021

01-12-2021 | Cervical Cancer | Gynecologic Cancers (LA Cantrell, Section Editor)

COVID-19 and Gynecologic Oncology: What Have We Learned?

Authors: Aurora Leibold, MD, Katyayani Papatla, MD, Kristen P. Zeligs, MD, Stephanie V. Blank, MD

Published in: Current Treatment Options in Oncology | Issue 12/2021

Login to get access

Opinion statement

COVID-19 has transformed the care we provide to gynecologic oncology patients. In addition to directly impacting the diagnosis and treatment of women with gynecologic cancer, it has affected our patient’s ability to undergo recommended surveillance and has made an impact on every caregiver providing care during this time. Herein we review the current literature on the impact of COVID-19 on gynecologic oncology and highlight new approaches and innovations that have resulted in gynecologic cancer care as a result of the pandemic. The impact of COVID-19 on the field of gynecologic oncology has been profound. In addition to directly impacting the diagnosis and treatment of women with cancer, it has also challenged the very ethics with which we practice medicine. The equitable distribution of resources is paramount to upholding the Hippocratic Oath which we all invoke. The COVID-19 pandemic has stripped this oath down to its very core, forcing all medical practitioners to scrutinize who gets what resources and when. As the pandemic continues to unfold, the question remains — in the setting of a strained and overburdened healthcare system, how do we maximize beneficence to one group of patients, while maintaining non-maleficence to others? As gynecologic oncologists, we are responsible for advocating for our patients to ensure that the quality of their cancer care is not compromised, while also not overutilizing resources that are sorely needed for the care of COVID-19 victims, and not making them more likely to succumb to COVID-19 by the very nature of the treatment we provide. The effects of the pandemic are far-reaching and broad, and many of these are yet to be determined. Future studies are needed to analyze how the above-utilized strategies in GYN cancer care during the pandemic will impact the long-term outcomes of our patients.
Literature
2.
go back to reference Frey MK, Fowlkes RK, Badiner NM, Fishman D, Kanis M, Thomas C, Christos PJ, Martin P, Gamble C, Balogun OD, Cardenes H, Gorelick C, Pua T, Nguyen L, Holcomb K, Chapman-Davis E. Gynecologic oncology care during the COVID-19 pandemic at three affiliated New York City hospitals. Gynecol Oncol. 2020;159(2):470–5.CrossRef Frey MK, Fowlkes RK, Badiner NM, Fishman D, Kanis M, Thomas C, Christos PJ, Martin P, Gamble C, Balogun OD, Cardenes H, Gorelick C, Pua T, Nguyen L, Holcomb K, Chapman-Davis E. Gynecologic oncology care during the COVID-19 pandemic at three affiliated New York City hospitals. Gynecol Oncol. 2020;159(2):470–5.CrossRef
4.
go back to reference •• Lara OD, O’Cearbhaill RE, Smith MJ, Sutter ME, Knisely A, McEachron J, Gabor LR, Jee J, Fehniger JE, Lee YC, Isani SS, Wright JD, Pothuri B. COVID-19 outcomes of patients with gynecologic cancer in New York City. Cancer. 2020;126(19):4294–303. This study was the first large series examining COVID-19 infections in a single sex with a specific cancer type. It provided early insight into the risk factors associated with increased morbidity and mortality among gynecologic oncology patients with COVID-19 infections.CrossRef •• Lara OD, O’Cearbhaill RE, Smith MJ, Sutter ME, Knisely A, McEachron J, Gabor LR, Jee J, Fehniger JE, Lee YC, Isani SS, Wright JD, Pothuri B. COVID-19 outcomes of patients with gynecologic cancer in New York City. Cancer. 2020;126(19):4294–303. This study was the first large series examining COVID-19 infections in a single sex with a specific cancer type. It provided early insight into the risk factors associated with increased morbidity and mortality among gynecologic oncology patients with COVID-19 infections.CrossRef
5.
go back to reference Ciavattini A, Delli Carpini G, Giannella L, Arbyn M, Kyrgiou M, Joura EA, Sehouli J, Carcopino X, Redman CW, Nieminen P, Cruickshank M, Gultekin M. European Federation for Colposcopy (EFC) and European Society of Gynaecological Oncology (ESGO) joint considerations about human papillomavirus (HPV) vaccination, screening programs, colposcopy, and surgery during and after the COVID-19 pandemic. Int J Gynecol Cancer. 2020;30(8):1097–100.CrossRef Ciavattini A, Delli Carpini G, Giannella L, Arbyn M, Kyrgiou M, Joura EA, Sehouli J, Carcopino X, Redman CW, Nieminen P, Cruickshank M, Gultekin M. European Federation for Colposcopy (EFC) and European Society of Gynaecological Oncology (ESGO) joint considerations about human papillomavirus (HPV) vaccination, screening programs, colposcopy, and surgery during and after the COVID-19 pandemic. Int J Gynecol Cancer. 2020;30(8):1097–100.CrossRef
7.
go back to reference Gorin SNS, Jimbo M, Heizelman R, Harmes KM, Harper DM. The future of cancer screening after COVID-19 may be at home. Cancer. 2021;127(4):498–503.CrossRef Gorin SNS, Jimbo M, Heizelman R, Harmes KM, Harper DM. The future of cancer screening after COVID-19 may be at home. Cancer. 2021;127(4):498–503.CrossRef
8.
go back to reference Polman NJ, de Haan Y, Veldhuijzen NJ, et al. Experience with HPV self-sampling and clinician-based sampling in women attending routine cervical screening in the Netherlands. Prev Med. 2019;125:5–11.CrossRef Polman NJ, de Haan Y, Veldhuijzen NJ, et al. Experience with HPV self-sampling and clinician-based sampling in women attending routine cervical screening in the Netherlands. Prev Med. 2019;125:5–11.CrossRef
9.
go back to reference Suh-Burgmann EJ, Alavi M, Schmittdiel J. Endometrial cancer detection during the coronavirus disease 2019 (COVID-19) pandemic. Obstet Gynecol. 2020;136(4):842–3.CrossRef Suh-Burgmann EJ, Alavi M, Schmittdiel J. Endometrial cancer detection during the coronavirus disease 2019 (COVID-19) pandemic. Obstet Gynecol. 2020;136(4):842–3.CrossRef
10.
go back to reference Akladios C, Azais H, Ballester M, et al. Recommendations for the surgical management of gynecological cancers during the COVID-19 pandemic - FRANCOGYN group for the CNGOF. J Gynecol Obstet Hum Reprod 2020;49. Akladios C, Azais H, Ballester M, et al. Recommendations for the surgical management of gynecological cancers during the COVID-19 pandemic - FRANCOGYN group for the CNGOF. J Gynecol Obstet Hum Reprod 2020;49.
11.
go back to reference •• Fader AN, Huh WK, Kesterson J, et al. When to operate, hesitate, and reintegrate: society of gynecologic oncology surgical considerations during the COVID-19 pandemic. Gynecol Oncol. 2020;158(2):236–43. Key SGO guidelines for surgical management of gynecologic oncology patients during the pandemic.CrossRef •• Fader AN, Huh WK, Kesterson J, et al. When to operate, hesitate, and reintegrate: society of gynecologic oncology surgical considerations during the COVID-19 pandemic. Gynecol Oncol. 2020;158(2):236–43. Key SGO guidelines for surgical management of gynecologic oncology patients during the pandemic.CrossRef
12.
go back to reference Matsuo K, Novatt H, Matsuzaki S, Hom MS, Castaneda AV, Licon E, Nusbaum DJ, Roman LD. Wait-time for hysterectomy and survival of women with early-stage cervical cancer: a clinical implication during the coronavirus pandemic. Gynecol Oncol. 2020;158(1):37–43.CrossRef Matsuo K, Novatt H, Matsuzaki S, Hom MS, Castaneda AV, Licon E, Nusbaum DJ, Roman LD. Wait-time for hysterectomy and survival of women with early-stage cervical cancer: a clinical implication during the coronavirus pandemic. Gynecol Oncol. 2020;158(1):37–43.CrossRef
13.
go back to reference Matsuo K, Huang Y, Matsuzaki S, Klar M, Wright JD. Effect of delay in surgical therapy for early-stage cervical cancer: an implication in the coronavirus pandemic. Eur J Cancer. 2020;139:173–6.CrossRef Matsuo K, Huang Y, Matsuzaki S, Klar M, Wright JD. Effect of delay in surgical therapy for early-stage cervical cancer: an implication in the coronavirus pandemic. Eur J Cancer. 2020;139:173–6.CrossRef
14.
go back to reference Bogani G, Ditto A, De Cecco L, Lopez S, Guerrisi R, Piccioni F, Micali A, Daidone MG, Raspagliesi F. Transmission of SARS-CoV-2 in surgical smoke during laparoscopy: a prospective, proof-of-concept study. J Minim Invasive Gynecol. 2020;S1553–4650(20):31200. Bogani G, Ditto A, De Cecco L, Lopez S, Guerrisi R, Piccioni F, Micali A, Daidone MG, Raspagliesi F. Transmission of SARS-CoV-2 in surgical smoke during laparoscopy: a prospective, proof-of-concept study. J Minim Invasive Gynecol. 2020;S1553–4650(20):31200.
15.
go back to reference de Leeuw RA, Burger NB, Ceccaroni M, Zhang J, Tuynman J, Mabrouk M, BarriSoldevila P, Bonjer HJ, Ankum P, Huirne J. COVID-19 and laparoscopic surgery: scoping review of current literature and local expertise. JMIR Public Health Surveill. 2020;6(2):e18928.CrossRef de Leeuw RA, Burger NB, Ceccaroni M, Zhang J, Tuynman J, Mabrouk M, BarriSoldevila P, Bonjer HJ, Ankum P, Huirne J. COVID-19 and laparoscopic surgery: scoping review of current literature and local expertise. JMIR Public Health Surveill. 2020;6(2):e18928.CrossRef
16.
go back to reference Kimmig R, Verheijen RHM, Rudnicki M, for SERGS Council. Robot assisted surgery during the COVID-19 pandemic, especially for gynecological cancer: a statement of the Society of European Robotic Gynaecological Surgery (SERGS). J Gynecol Oncol. 2020;31(3):e59.CrossRef Kimmig R, Verheijen RHM, Rudnicki M, for SERGS Council. Robot assisted surgery during the COVID-19 pandemic, especially for gynecological cancer: a statement of the Society of European Robotic Gynaecological Surgery (SERGS). J Gynecol Oncol. 2020;31(3):e59.CrossRef
17.
go back to reference • Glasbey JC, Nepogodiev D, Simoes JFF, et al. Elective cancer surgery in COVID-19-free surgical pathways during the SARS-CoV-2 pandemic: an international, multicenter, comparative cohort study. J Clin Oncol. 2021;39(1):66–78. This paper demonstrates a critical component of the safe resumption of elective surgery during a pandemic. The methods described by the authors demonstrate that when able, complete segregation of operative pathways can allow for the resumption of elective surgery while still protecting patients from COVID-19 complications.CrossRef • Glasbey JC, Nepogodiev D, Simoes JFF, et al. Elective cancer surgery in COVID-19-free surgical pathways during the SARS-CoV-2 pandemic: an international, multicenter, comparative cohort study. J Clin Oncol. 2021;39(1):66–78. This paper demonstrates a critical component of the safe resumption of elective surgery during a pandemic. The methods described by the authors demonstrate that when able, complete segregation of operative pathways can allow for the resumption of elective surgery while still protecting patients from COVID-19 complications.CrossRef
18.
go back to reference • Elledge CR, Beriwal S, Chargari C, et al. Radiation therapy for gynecologic malignancies during the COVID-19 pandemic: international expert consensus recommendations. Gynecol Oncol. 2020;158(2):244–53. Expert international consensus from radiation oncology specialists regarding the prioritization of radiation therapy in gynecologic oncology patients.CrossRef • Elledge CR, Beriwal S, Chargari C, et al. Radiation therapy for gynecologic malignancies during the COVID-19 pandemic: international expert consensus recommendations. Gynecol Oncol. 2020;158(2):244–53. Expert international consensus from radiation oncology specialists regarding the prioritization of radiation therapy in gynecologic oncology patients.CrossRef
19.
go back to reference Williams VM, Kahn JM, Harkenrider MM, et al. COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation. Brachytherapy. 2020;19(4):401–11.CrossRef Williams VM, Kahn JM, Harkenrider MM, et al. COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation. Brachytherapy. 2020;19(4):401–11.CrossRef
20.
go back to reference Han K, Mendez L, D’Souza D, et al. Management of gynecologic cancer: choosing radiotherapy wisely by 3 Southern Ontario academic centers during the COVID-19 pandemic. Radiother Oncol. 2020;151:15–6.CrossRef Han K, Mendez L, D’Souza D, et al. Management of gynecologic cancer: choosing radiotherapy wisely by 3 Southern Ontario academic centers during the COVID-19 pandemic. Radiother Oncol. 2020;151:15–6.CrossRef
21.
go back to reference Yeramilli D, Xu A, Gillespie E, et al. Palliative radiation therapy for oncologic emergencies in the setting of COVID-19: approaches to balancing risks and benefits. Adv Radiat Oncol. 2020;5(4):589–94.CrossRef Yeramilli D, Xu A, Gillespie E, et al. Palliative radiation therapy for oncologic emergencies in the setting of COVID-19: approaches to balancing risks and benefits. Adv Radiat Oncol. 2020;5(4):589–94.CrossRef
22.
go back to reference •• Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan. China JAMA Oncol. 2020;6(7):1108–10. This is an early landmark study demonstrating the higher incidence of COVID-19 infections among patients with solid cancers out of a large cohort of COVID-19 patients in Wuhan, China.CrossRef •• Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan. China JAMA Oncol. 2020;6(7):1108–10. This is an early landmark study demonstrating the higher incidence of COVID-19 infections among patients with solid cancers out of a large cohort of COVID-19 patients in Wuhan, China.CrossRef
23.
go back to reference •• Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–7. Another landmark study from China demonstrating the increased risks of COVID-19 infection in cancer patients. This paper demonstrates the vulnerability of this population, including increased rates of ICU admission, mechanical ventilation, and death.CrossRef •• Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–7. Another landmark study from China demonstrating the increased risks of COVID-19 infection in cancer patients. This paper demonstrates the vulnerability of this population, including increased rates of ICU admission, mechanical ventilation, and death.CrossRef
24.
go back to reference • Pothuri B, Alvarez Secord A, Armstrong DK, Chan J, Fader AN, Huh W, Kesterson J, Liu JF, Moore K, Westin SN, Naumann RW. Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis. Gynecol Oncol. 2020;158(1):16–24. Excellent recommendations for the approach to systemic therapy and considerations for clinical trial enrollment for gynecologic oncology patients during the pandemic.CrossRef • Pothuri B, Alvarez Secord A, Armstrong DK, Chan J, Fader AN, Huh W, Kesterson J, Liu JF, Moore K, Westin SN, Naumann RW. Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis. Gynecol Oncol. 2020;158(1):16–24. Excellent recommendations for the approach to systemic therapy and considerations for clinical trial enrollment for gynecologic oncology patients during the pandemic.CrossRef
25.
go back to reference Monk BJ, Coleman RL, Moore KN, Herzog TJ, Secord AA, Matulonis UA, Slomovitz BM, Guntupalli SR, O’Malley DM. COVID-19 and ovarian cancer: exploring alternatives to intravenous (IV) therapies. Gynecol Oncol. 2020;158(1):34–6.CrossRef Monk BJ, Coleman RL, Moore KN, Herzog TJ, Secord AA, Matulonis UA, Slomovitz BM, Guntupalli SR, O’Malley DM. COVID-19 and ovarian cancer: exploring alternatives to intravenous (IV) therapies. Gynecol Oncol. 2020;158(1):34–6.CrossRef
26.
go back to reference Vetter MH, Smrz SA, Copeland LJ, Cohn DE. Chemotherapy directly followed by poly(ADP-ribose) polymerase inhibition as an alternative to surgery in patients with BRCA-mutated ovarian cancer: a potential management strategy in the era of coronavirus disease 2019. Am J Obstet Gynecol. 2020;223(3):469–70.CrossRef Vetter MH, Smrz SA, Copeland LJ, Cohn DE. Chemotherapy directly followed by poly(ADP-ribose) polymerase inhibition as an alternative to surgery in patients with BRCA-mutated ovarian cancer: a potential management strategy in the era of coronavirus disease 2019. Am J Obstet Gynecol. 2020;223(3):469–70.CrossRef
28.
go back to reference Xia Y, Jin R, Zhao J, et al. Risk of COVID-19 for cancer patients. Lancet Oncol. 2020;21(4):e180.CrossRef Xia Y, Jin R, Zhao J, et al. Risk of COVID-19 for cancer patients. Lancet Oncol. 2020;21(4):e180.CrossRef
29.
go back to reference Mancebo G, Solé-Sedeño J-M, Membrive I, Taus A, Castells M, Serrano L, Carreras R, Miralpei E. Gynecologic cancer surveillance in the era of SARS-CoV-2 (COVID-19). Int J Gynecol Cancer. 2020;0:1–6. Mancebo G, Solé-Sedeño J-M, Membrive I, Taus A, Castells M, Serrano L, Carreras R, Miralpei E. Gynecologic cancer surveillance in the era of SARS-CoV-2 (COVID-19). Int J Gynecol Cancer. 2020;0:1–6.
30.
go back to reference Lai J, Ma S, Wang Y, et al. Factors associated with mental health outcomes among health care workers exposed to coronavirus disease 2019. JAMA Netw Open. 2020;3(3):e203976.CrossRef Lai J, Ma S, Wang Y, et al. Factors associated with mental health outcomes among health care workers exposed to coronavirus disease 2019. JAMA Netw Open. 2020;3(3):e203976.CrossRef
31.
go back to reference Thomaier L, Teoh D, Jewett P, Beckwith H, Parsons H, Yuan J, Blaes AH, Lou E, Hui JYC, Vogel RI. Emotional health concerns of oncology physicians in the United States: fallout during the COVID-19 pandemic. PLoS ONE. 2020;15(11):e0242767.CrossRef Thomaier L, Teoh D, Jewett P, Beckwith H, Parsons H, Yuan J, Blaes AH, Lou E, Hui JYC, Vogel RI. Emotional health concerns of oncology physicians in the United States: fallout during the COVID-19 pandemic. PLoS ONE. 2020;15(11):e0242767.CrossRef
32.
go back to reference Wu Y, Wang J, Luo C, et al. A comparison of burnout frequency among oncology physicians and nurses working on the front lines and usual wards during the COVID-19 epidemic in Wuhan, China. J Pain Symptom Manage. 2020;60(1):e60–5.CrossRef Wu Y, Wang J, Luo C, et al. A comparison of burnout frequency among oncology physicians and nurses working on the front lines and usual wards during the COVID-19 epidemic in Wuhan, China. J Pain Symptom Manage. 2020;60(1):e60–5.CrossRef
33.
go back to reference Shanafelt T, Ripp J, Trockel M. Understanding and addressing sources of anxiety among health care professionals during the COVID-19 pandemic. JAMA. 2020;323(21):2133–4.CrossRef Shanafelt T, Ripp J, Trockel M. Understanding and addressing sources of anxiety among health care professionals during the COVID-19 pandemic. JAMA. 2020;323(21):2133–4.CrossRef
34.
go back to reference Zimmerman BS, Seidman D, Berger N, Cascetta KP, Nezolosky M, Trlica K, Ryncarz A, Keeton C, Moshier E, Tiersten A. Patient perception of telehealth services for breast and gynecologic oncology care during the COVID-19 pandemic: a single center survey-based study. J Breast Cancer. 2020;23(5):542–52.CrossRef Zimmerman BS, Seidman D, Berger N, Cascetta KP, Nezolosky M, Trlica K, Ryncarz A, Keeton C, Moshier E, Tiersten A. Patient perception of telehealth services for breast and gynecologic oncology care during the COVID-19 pandemic: a single center survey-based study. J Breast Cancer. 2020;23(5):542–52.CrossRef
35.
go back to reference Mojdehbakhsh RP, Rose S, Peterson M, Rice L, Spencer R. A quality improvement pathway to rapidly increase telemedicine services in a gynecologic oncology clinic during the COVID-19 pandemic with patient satisfaction scores and environmental impact. Gynecol Oncol Rep. 2021;22:100708.CrossRef Mojdehbakhsh RP, Rose S, Peterson M, Rice L, Spencer R. A quality improvement pathway to rapidly increase telemedicine services in a gynecologic oncology clinic during the COVID-19 pandemic with patient satisfaction scores and environmental impact. Gynecol Oncol Rep. 2021;22:100708.CrossRef
36.
go back to reference Ramirez PT, Chiva L, Eriksson AGZ, Frumovitz M, Fagotti A, Gonzalez Martin A, Jhingran A, Pareja R. COVID-19 global pandemic: options for management of gynecologic cancers. Int J Gynecol Cancer. 2020;30(5):561–3.CrossRef Ramirez PT, Chiva L, Eriksson AGZ, Frumovitz M, Fagotti A, Gonzalez Martin A, Jhingran A, Pareja R. COVID-19 global pandemic: options for management of gynecologic cancers. Int J Gynecol Cancer. 2020;30(5):561–3.CrossRef
37.
go back to reference Uwins C, Bhandoria GP, Shylasree T, et al. COVID-19 and gynecological cancer: a review of the published guidelines. Int J Gynecol Cancer. 2020;30:1424–33.CrossRef Uwins C, Bhandoria GP, Shylasree T, et al. COVID-19 and gynecological cancer: a review of the published guidelines. Int J Gynecol Cancer. 2020;30:1424–33.CrossRef
38.
go back to reference Moran HK, Brooks JV, Spoozak L. Undergoing active treatment for gynecologic cancer during COVID-19: a qualitative study of the impact on healthcare and social support. Gynecol Oncol Rep. 2020;34:100659.CrossRef Moran HK, Brooks JV, Spoozak L. Undergoing active treatment for gynecologic cancer during COVID-19: a qualitative study of the impact on healthcare and social support. Gynecol Oncol Rep. 2020;34:100659.CrossRef
Metadata
Title
COVID-19 and Gynecologic Oncology: What Have We Learned?
Authors
Aurora Leibold, MD
Katyayani Papatla, MD
Kristen P. Zeligs, MD
Stephanie V. Blank, MD
Publication date
01-12-2021
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 12/2021
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-021-00905-5

Other articles of this Issue 12/2021

Current Treatment Options in Oncology 12/2021 Go to the issue

Palliative and Supportive Care (MP Davis, Section Editor)

Treating Chronic Pain with Buprenorphine—The Practical Guide

Head and Neck Cancer (JL Geiger, Section Editor)

Overview and Emerging Trends in the Treatment of Osteoradionecrosis

Neuro-oncology (GJ Lesser, Section Editor)

Systemic Therapy for Lung Cancer Brain Metastases

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine